Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Synergy Pharmaceuticals Inc

+ Add to Watchlist

SGYPU:US

9.8500 USD 0.4200 4.45%

As of 20:10:00 ET on 03/26/2015.

Snapshot for Synergy Pharmaceuticals Inc (SGYPU)

Open: 10.2500 Day's Range: 9.8500 - 10.2500 Volume: 2,655
Previous Close: 9.4300 52wk Range: 5.3400 - 13.9500 1-Yr Rtn: -

Stock Chart for SGYPU

No chart data available.
  • SGYPU:US 9.8500
  • 1D
  • 1M
  • 1Y
9.4300
Interactive SGYPU Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for SGYPU

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. SPX -
Earnings Per Share (ttm) -
Est. EPS -
Est. PEG Ratio -
Market Cap (M USD) 0.00
Shares Outstanding (M) 0.00
30 Day Average Volume 271
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/13/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for SGYPU

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for SGYPU

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead drug candidate is a a guanylyl cyclase C (GC-C) receptor agonist, to treat gastrointestinal disorders, primarily chronic constipation and constipation-predominant irritable bowel syndrome (IBS-C).

Gary S JacobChairman/President/CEOPatrick H GriffinChief Medical Officer
Kunwar ShailubhaiExec VP/Chief Scientfic OfficerBernard F DenoyerSenior VP:Finance/Secretary
More Company Profile & Key Executives for SGYPU

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil